| Name | Zotarolimus |
| Description | Zotarolimus (ABT-578), an analogue of rapamycin, inhibits FKBP-12 (IC50= 2.8 nM). |
| Cell Research | Cell proliferation is assayed by measuring tritiated thymidine incorporation in vitro. Human coronary artery cells (hCa) are seeded into tissue culture flasks for expansion and applied to 96-well plates at desired density in complete media (5000 hCaSMC; 10 000 hCaEC). After 2 days, complete media is replaced with incomplete media to synchronize cells and induce G0 state. Two days later, incomplete media are removed and replaced with complete media (serum/growth factors) to induce G0 to G1 transition. Complete media also contain drug at desired concentrations to determine its effects on cell proliferation. On day 7, 3H-thymidine is added to cells to monitor DNA synthesis, and cells are harvested after overnight incorporation of radioactivity. After an incubation period of 72 h, 25 μL (1 μCi/well) of 3H-thymidine are added to each well. The cells are incubated at 37°C for 16-18 h to allow for incorporation of 3H-thymidine into newly synthesized DNA and the cells harvested onto 96-well plates containing bonded glass fibre filters . The filter plates are air-dried overnight, MicroScint-20 (25 μL) added to each filter well and counted. Drug activity is determined by the inhibition of 3H-thymidine incorporation into newly synthesized DNA relative to cells grown in complete media. (Only for Reference) |
| Kinase Assay | zotarolimus (10 pM-1 μM) in buffer A (2% BSA and 0.2% Tween-20 in D-PBS) is used in the assay of Binding Affinity to FKBP12. |
| Animal Research | Male Sprague-Dawley rats was administrate by intravenous or oral Zotarolimus（2.5 mg/kg）dissolved inethanol: propylene glycol: cremophor EL: D5W vehicle (20: 30: 2: 48, by volume). |
| In vitro | In smooth muscle cell （IC50=2.9 nM）and endothelial cell （IC50=2.6 nM）,Zotarolimus effectively inhibits cells proliferation. |
| In vivo | Zotarolimus potently inhibits adjuvant DTH(ED50=1.72 mg/kg/day), EAE(ED50=1.17 mg/kg/day), and cardiac allograft rejection(ED50=3.71 mg/kg/day) . |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 3.3 mg/mL (3.42 mM), Sonication is recommended.
Ethanol : 93 mg/mL (96.25 mM), Sonication is recommended.
DMSO : 93 mg/mL (96.25 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Zotarolimus | stents | restenosis | Rapamycin | Inhibitor | inhibit | immunosuppressant | FKBP-12 | drug-eluting | disease | coronary | artery | ABT578 | ABT 578 | A-179578 | A179578 |
| Inhibitors Related | Stearamide | L-Leucine | 4-Vinylcyclohexene Dioxide | Resveratrol | N-Hydroxyphthalimide | L-Proline | Metformin | Methyl eugenol | Metformin hydrochloride | (E/Z)-10-Hydroxy-2-decenoic acid | Dihydromyricetin | Rapamycin |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | HIF-1 Signaling Pathway Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Obesity Compound Library | Anti-Cancer Metabolism Compound Library | Post-Translational Modification Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Anti-Infection Compound Library | Anti-Liver Cancer Compound Library |
United States
